EGFR and non-small cell lung carcinoma: This is in line with already published data on KL mice phenotype indicating an improved therapeutic response with pan-ERBB inhibitors compared to EGFR inhibitors (Kruspig et al., 2018; Moll et al., 2018; Talwelkar et al., 2019) further suggesting that our i.v. transplantation model is a reliable preclinical tool for NSCLC therapy and metastasis analysis.